A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year…

Overview of attention for article published in BMC Cancer, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 3 news stories from 3 outlets.

(CNN Español) -- La vacuna contra el virus del papiloma humano (VPH) se empezó a usar a mediados de la década de 2000.

Ursprünglich als Drei-Dosen-Impfstoff empfohlen, wurden diese reduziert zu zwei von der WHO im Jahr 2017.

Inicialmente recomendada como una vacuna de tres dosis, estas fueron reducidas a dos por la OMS en el 2017.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.